(NASDAQ: RPRX) Royalty Pharma's forecast annual revenue growth rate of 19.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 152.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.68%.
Royalty Pharma's revenue in 2025 is $2,263,576,000.On average, 2 Wall Street analysts forecast RPRX's revenue for 2025 to be $1,710,208,573,886, with the lowest RPRX revenue forecast at $1,692,989,341,334, and the highest RPRX revenue forecast at $1,727,428,382,891. On average, 2 Wall Street analysts forecast RPRX's revenue for 2026 to be $1,846,474,032,220, with the lowest RPRX revenue forecast at $1,788,307,025,404, and the highest RPRX revenue forecast at $1,904,641,615,490.
In 2027, RPRX is forecast to generate $2,022,165,428,459 in revenue, with the lowest revenue forecast at $2,007,231,832,714 and the highest revenue forecast at $2,037,099,024,203.